HCV: The Correctional Conundrum

Anne S. De Groot, M.D.*, Brown Medical School, Editor, HEPP News

Treatment of Hepatitis C (HCV) is emerging as the most controversial subject in correctional health care. Much of the controversy around HCV testing and treatment in corrections is related to delayed recognition of the important role incarcerated individuals play in the transmission of hepatitis in the communities after they are released. State and Federal public health officials have been slow to recognize the potential benefits of screening, educating, and where possible, vaccinating incarcerated persons to prevent morbidity and mortality associated with viral hepatitis.

The Centers for Disease Control (CDC) took action this Spring, convening a meeting on Hepatitis in correctional settings that was attended by more than 100 federal and state correctional healthcare professionals. Representatives of correctional organizations (ACA, NCCHC) and representatives from federal agencies such as the OSHA and NIOSH also attended the meeting. CDC speakers discussed the need to expand HBV and HCV interventions, including screening, education, vaccination, and treatment of chronic hepatitis in correctional settings. Guidelines for HCV and HBV management incorporating some of the discussion points will be issued by the CDC as a supplement to the MMWR in the Fall. While sources of funding for increased hepatitis interventions in corrections were not specifically addressed at this meeting, promoting correctional settings as outposts for public health activities may ultimately lead to increased financial support from federal and state sources for correctional treatment initiatives.

In keeping with this new national focus on hepatitis in corrections, HEPP News is dedicating two of the next three issues to updates on hepatitis management. This issue addresses HCV in corrections and summarizes discussions at the CDC meeting. The second article, scheduled for June 2001, will take up the topic of Hepatitis B and Hepatitis A immunizations in correctional settings.

HCV Epidemiology
HCV and HBV outstrip HIV in terms of sheer numbers of inmates living with these two infec-

Figure 1. Blood Born Diseases in Corrections

rates in millions)

HCV: The Correctional Conundrum

HEPP News announces a new focus on HEPATITIS. (See Newsflashes)

Inmates At Risk
Non hispanic blacks and hispanics have higher rates of HCV and HBV infection and chronic disease than whites; most cases of HCV and HBV infections are found among persons who are male, members of minority populations, and 30 to 49 years of age. These race and class-related risk factors for hepatitis infection probably contribute to the current concentration of HCV and HBV-infected persons in prisons and jails.

According to a recent analysis by Ted Hammett for the NJI and the NCCHC’s report to Congress, between 1.0 to 1.25 million individuals harboring chronic HCV infection were released from prisons and jails in the U.S. in 1996, or approximately 30% (29 to 32%) of the total population living with HCV in the U.S. The prevalence of HCV infection among U.S. prisoners is at least 10 fold higher than the estimated 2% prevalence in the general population. This ratio is based on estimates that 17% of

Continued on page 2

WHAT’S INSIDE
HEPPigram Part I pg 6
HCV101 pg 8
News Flashes pg 9
Self-Assessment Test pg 10
HCV... (continued from page 1) state inmates are infected with HCV. HCV infection rates have ranged from 28% (Texas) to 67% of a higher risk subpopulation of inmates (those with abnormal liver function tests or who are known to have HIV infection) in New Jersey. Reflecting their higher rate of participation in HIV and HCV risk behaviors, incarcerated women exhibited about a third higher HCV co-infection rate than incarcerated men.25

Rationale for Screening
Approximately 50% of persons with hepatitis are unaware of their hepatitis infection.22 Testing for infection informs the patient and physician about the potential for and possible existence of liver damage. It should serve as an important prompt for a discussion about risky behaviors and transmission to others.23 The CDC lists correctional institutions, HIV counseling and testing sites, and drug and STD treatment programs as sites where hepatitis screening and interventions should take place. (See Table 2 for recommendations.)

- Reducing the cost of screening
If the cost of screening an incarcerated population for HCV appears to be prohibitive, targeted screening can reduce the cost of screening and still identify most HCV at-risk individuals. For example, in a Wisconsin study of HCV screening in a local prison, 60.5% of HCV infections were identified by screening those who had history of IDU. By including any individuals who also had an ALT > 51, the facility identified 79.6% of HCV infections. Adding a history of liver disease to the criteria for testing allowed the identification of 83.6% of HCV-infected individuals. When individuals who were HBV+ were also screened, the correctional facility identified 90.8% of the HCV infections. The cost of testing was reduced by two thirds (compared to mass screening) using their criteria, and was very effective.25

Treatment of HCV
For those who are to be treated, initial treatment of chronic HCV with ribavirin/interferon alpha is now the standard of care in community settings. Many correctional facilities are in the process of developing protocols for deciding which patients will be eligible for treatment (see the Correctional Medical Services triage form HEPPigram Part I on page 6 for an example).

- Treatment selection criteria
Criteria for HCV treatment may vary slightly from one correctional system to another. In general, eligible patients (1) have evidence of persistent HCV infection and inflammation based on liver function test abnormalities and detectable virus in the blood stream; (2) have enough time left in their sentence to allow for completion of treatment (from six to 12 months) (3) are committed to a life free from substance and alcohol abuse; and (4) are educated about potential HCV treatment side effects and willing to adhere to an arduous course of treatment. (See HEPPigram on page 6 for guidance on selecting patients for HCV treatment.)

Standard therapy is to provide daily treatment with Ribavirin (usually five to six pills divided into two doses) and thrice-weekly interferon injections. (See HCV 101 on page 8 for dosing and side effects of treatment regimens.) Pegylated interferon, a new form of interferon that permits once-weekly dosing, is available as PEG-Intron (peginterferon alpha-2b), and Pegasys is expected to be approved by the FDA later this Spring. Monotherapy is currently only used if the patient cannot take Ribavirin due to toxicities or side-effects.

Duration of treatment
Current recommendations on the duration of treatment are as follows:
Duration of Combination therapy depends on viral genotype:
- HCV genotype 2 or 3: A 24-week (six month) course of combination therapy yields results equivalent to those of a 48-week (12 month) course.
- HCV genotype 1: A 48-week (12 month) course yields a significantly better sustained response rate than does six months of treatment.

Duration of Interferon monotherapy: 48-weeks, regardless of genotype.

Expected Response: Combination Therapy versus Monotherapy
Combination therapy consistently yields higher rates of sustained response than monotherapy. (A sustained response implies that HCV RNA remains undetectable for six months or more after therapy stops.) With combination therapy, 40% of treatment-naïve patients respond. Patients with genotype-1 have sustained response rates of 25 to 30% (slightly better response rates are seen with lower baseline HCV viral loads). Non-genotype-1 patients achieve response rates of 60 to 65%. Other factors that increase the likelihood of a response to therapy include age <45, female gender, and mild (rather than advanced) chronic inflammation on liver biopsy. Histologic improvement occurs in 86% of patients who achieve a sustained response (SVR) and 39% of patients who relapse after initial response to combination therapy. Just as with HIV therapy, adherence is critical to obtain maximal response. Adherence to therapy has also been shown to increase the likelihood of a response to therapy. The SVR increases from 40% to 48% when patients receive at least 80% of both their interferon dose and their ribavirin dose for > 80% of the recommended duration.29

- Pegylated delivery: Another Step Forward in Hepatitis C Therapy
Pegylated forms of interferon allow once-weekly dosing, which may increase patient adherence and prolong therapy duration.

Hepatitis and HIV Disease Prevalence

<table>
<thead>
<tr>
<th>Hepatitis and HIV prevalence in US populations</th>
<th>HCV</th>
<th>HBV</th>
<th>HIV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic Infections</td>
<td>4.5 million</td>
<td>1.2 million</td>
<td>0.8 million</td>
</tr>
<tr>
<td>New Infections per year</td>
<td>35,000</td>
<td>120,000</td>
<td>40,000</td>
</tr>
<tr>
<td>Deaths per year</td>
<td>8,000</td>
<td>5,000</td>
<td>18,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hepatitis and HIV prevalence among inmates released from prisons and jails*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of infected inmates released</td>
</tr>
<tr>
<td>% of US population</td>
</tr>
</tbody>
</table>

*CDC, Harold Margolis, Hepatitis Branch.
**Hammet et al. noted an extreme lack of HBV data on correctional populations. These numbers are rough period prevalence estimates based on studies done in California (1994) and New York (1997) correctional systems.

This figure shows the prevalence of HCV in certain state correctional populations. Percentages are shown by gender when data were available. These prevalence studies are not necessarily comparable across states because different methods were used to compile the data. HCV prevalence in reporting states is the following: California: 40% of men and 54% of women; Connecticut: 32% of women; Colorado: 30%; Maryland: 38%; Massachusetts: 20.7% (Hamden County); Texas: 28% of the men and 37% of women; Virginia: 30-40%; Washington: 30-40%; Wisconsin: 21% of women, 12.4% of men, 13.2% overall; Pennsylvania: 13%; Arizona: 31.3%.21

<table>
<thead>
<tr>
<th>Figure 2. Prevalence of HCV Infection in Selected States</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>% of US population</strong></td>
</tr>
<tr>
<td>AZ</td>
</tr>
<tr>
<td>10%</td>
</tr>
</tbody>
</table>

Detailed figures and data are available in Tables 1 and 2. For more information, visit HEPP News online at www.hivcorrections.org.

Continued on page 4
Dear Colleagues,

As our experience with highly active antiretroviral therapy and long-term survival expands, we now manage comorbid diseases that never had time to manifest in the past, such as Hepatitis C (HCV). HCV infection contributes to the deaths of an estimated 8,000 - 10,000 Americans each year. This toll is expected to triple by the year 2010 and exceed the number of annual deaths due to AIDS, according to the CDC.

Hepatitis C infection shares many of the epidemiologic risk factors associated with HIV. Indeed, coinfection rates in the HIV+ population average 30-35%, but can be as high as 100% in specific settings. Thus, testing for the co-related virus is a must in order to provide early intervention and evaluation, as well as begin risk reduction counseling and training.

Treatment options for both viruses are also unclear. Some HIV antiretrovirals appear to have a greater risk for hepatotoxicity than others, independently of HCV infection. The treatment balance lies in the ability to effectively evaluate the HCV infection with not only viral load, genotype and imaging, but also with liver biopsy as chemical hepatitis often does not correlate with the degree of liver injury present.

As with many other chronic medical conditions, morbidity and/or mortality attributable to HCV may not manifest itself until well after the end of incarceration. Consequently, correctional systems, when faced with the dilemma of prioritizing treatment for HCV, may choose to spend the funds otherwise, or not at all. Much of the controversy is related to the cost of a therapy that is difficult to administer and, in many cases, ineffective. Additionally, the therapy in most cases is being given to IDUs who are in forced institutional abstinence, have not and will not have drug treatment, and will therefore probably be promptly reinfected upon release.

Despite these concerns, some state medical directors have lead the way and adopted clear protocols for the screening and treatment of HCV in their facilities. These visionaries are mindful that a year 2001 dollar spent on treatment may reduce the cost (to society) of caring for patients who may require liver transplants in 20 to 30 years. Furthermore, combination therapy of HCV is leading to higher rates of cure (up to 88% in selected patients), therefore, the overall cost effectiveness of HCV interventions in corrections is improving. Obviously, more data are needed to more concretely guide our treatment programs. Until then, we can only continue to do the best with what information we have.

After reviewing this issue, readers should be able to describe the rationale for HCV testing and treatment, review the interactions between HCV and HIV, describe the risk of HCV infection for inmates and correctional workers, and provide preliminary information on new formulations of therapy. Thank you for your continued support of HEPP News!

Sincerely,

Michael T. Wong, MD,
Assistant Professor of Medicine, Division of Infectious Diseases, Beth Israel Deaconess Medical Center
HCV... (continued from page 2)

weekly dosing, improving adherence to therapy and possibly improving response to therapy. A phase III study demonstrated that the combination of peginterferon alfa-2b (1.5 mcg/kg once weekly) plus ribavirin was significantly more effective than the combination of standard interferon alfa-2b plus ribavirin, particularly in patients with genotype 1 virus. SVR rates in this study were dependent on the actual dose received. Overall, patients who received >10.6 mg/kg/daily of ribavirin plus 1.5 mcg/kg/QW of peginterferon alfa-2b achieved a SVR of 61%. The SVR in genotype 1 patients was 48% and the SVR in non-genotype 1 patients was 88%. This study also demonstrated that these response rates could be further increased if patients were able to maintain adherence. Regardless of genotype, patients who received the recommended combination regimen and received >80% of their treatment had a higher sustained response than those who received <80% of their treatment (72% vs. 46%). Genotype 1 patients who received the optimal weight-based dose of peginterferon alfa-2b plus ribavirin and adhered to at least 80% of their regimen achieved a SVR of 63%. Similar patients with genotype 2 or 3 infection achieved a SVR of 94%,.

Liver Biopsy
The need for confirming the extent of damage to the liver by HCV and chronic HBV infection is another area of debate, since obtaining liver biopsies can be both costly and logistically complicated in correctional settings. Liver function tests can be normal in patients with rather advanced cirrhotic features. Likewise, liver function tests may be consistently elevated in Hepatitis C patients with normal histology. Some state correctional systems do not routinely perform liver biopsies prior to initiating treatment, because of cost and logistical difficulties. Other states (e.g. FL) feel biopsies are the only real way to measure disease progression over time and therefore have made arrangements to do them on site at very reduced costs ($200 per biopsy). Depending on the cost of obtaining a liver biopsy, electing to treat all incarcerated individuals who meet the criteria for treatment may be more cost-effective, for society as a whole, than management by biopsy.

Lowest cost intervention: Education
The lowest cost intervention for the prevention of hepatitis infection is education. Given the risk of acquiring HCV (not to mention HIV), all bloodborne pathogen screening events should lead to careful discussion of the risks of HBV and HIV infection (for those patients who have negative hepatitis serologies). The risk of transmitting hepatitis should also be made very clear (see Resources on page 9 for educational materials).

The impact of continued drug use should also be made very clear to patients, especially those who are not yet HCV infected.

Young injection drug users (IDUs) acquire HCV infection at rates four times higher than the rate of acquisition of HIV; after 5 years of injection drug use, 90% of IDUs are HCV infected. For those inmates already infected with HCV, education should be provided on the impact of alcohol abuse on HCV progression (four fold increase in risk of progression, risk of liver damage directly correlated with alcohol intake) and the risk of transmission to uninfected sexual partners. Inmates who have HCV infection should, at the very least, be educated about options for treatment even if they are not eligible for treatment while incarcerated (see Resources on page 9 for expanded access programs).

Additional considerations
Another lower (but no-cost) intervention is vaccination. For HCV infected patients, vaccination against HBV and HIV is routine-ly recommended, as these relatively inexpensive vaccines may reduce the risk of fulminant liver failure and the need for liver transplantation for HCV-infected patients. A new schedule of HBV vaccination (three shots at 0, 1, and 4 months) has received approval. The first shot provides up to 50% protection, and the series does have efficacy even if prolonged over several years, so the new CDC guidelines are expected to encourage HBV vaccination even in jail settings.

Should patients be ineligible for treatment due to lack of time to complete the treatment, they should be provided with the hotline numbers to access free HCV treatments, if noted however that the cost savings that may accrue from treatment of prisoners are primarily to society as a whole. While treatment of incarcerated individuals for hepatitis and HIV is the right thing to do and can extraordinarily benefit the public health, it is not realistic to expect correctional systems to shoulder this financial burden without assistance.

Management
Since the incidence of side effects to HCV combination therapy can be relatively high, and it can be difficult for incarcerated patients to quickly access their clinician to report side effects, it is important to:

- spend time preparing the patient for the potential treatment-related side effects,

Consider following the patients in a dedicated hepatitis clinic.

<table>
<thead>
<tr>
<th>TABLE 2. HCV / HBV Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Persons who should be tested routinely for hepatitis include:</td>
</tr>
<tr>
<td>- Patients residing in correctional facilities</td>
</tr>
<tr>
<td>- IDU, including those who injected once or a few times and do not currently consider themselves to be drug users.</td>
</tr>
<tr>
<td>- Persons with selected medical conditions, including:</td>
</tr>
<tr>
<td>- Persons who received clotting factor concentrates produced before 1987</td>
</tr>
<tr>
<td>- Persons ever on chronic hemodialysis;</td>
</tr>
<tr>
<td>- Persons with persistently abnormal ALT levels.</td>
</tr>
<tr>
<td>- Persons who received blood transfusions, blood components, or organ transplantation before July 1992</td>
</tr>
<tr>
<td>- Persons diagnosed with HIV infection and sexual partners of persons diagnosed with HIV infection</td>
</tr>
<tr>
<td>- Healthcare and correctional workers after needle sticks, sharps, or mucosal exposures to HCV-positive blood.</td>
</tr>
</tbody>
</table>

Source: Modified from MMWR, 1998

<table>
<thead>
<tr>
<th>TABLE 3. Monitoring HCV Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table also applies to HCV/HIV patients</td>
</tr>
<tr>
<td>- Baseline</td>
</tr>
<tr>
<td>- HIV viral load, CD4, CBC, LFTs, Chem panel, HCV load, genotype</td>
</tr>
<tr>
<td>- Screen for co-morbid disease</td>
</tr>
<tr>
<td>- Depression screen (consider anti-depressant prophylaxis)</td>
</tr>
<tr>
<td>- Week 2</td>
</tr>
<tr>
<td>- CBC</td>
</tr>
<tr>
<td>- If anemic; erythropoeitin</td>
</tr>
<tr>
<td>- 4 week intervals</td>
</tr>
<tr>
<td>- CBC, LFTs, Chem panel</td>
</tr>
<tr>
<td>- Evaluate mood, adverse effects</td>
</tr>
<tr>
<td>- 12 week intervals</td>
</tr>
<tr>
<td>- HCV VL, HIV VL, CD4</td>
</tr>
<tr>
<td>- Evaluate for drug-drug interactions</td>
</tr>
<tr>
<td>- Screen for IFN-associated thyroid dysfunction (TSH)</td>
</tr>
<tr>
<td>- Check HCV VL week 12 and 24</td>
</tr>
<tr>
<td>- Week 12:</td>
</tr>
<tr>
<td>- HCV RNA &gt; 1 log reduction</td>
</tr>
<tr>
<td>- Week 24:</td>
</tr>
<tr>
<td>- HCV RNA undetectable</td>
</tr>
<tr>
<td>- If genotype 1, continue TX for 48 weeks. If non-genotype 1, stop therapy after 24 weeks.</td>
</tr>
<tr>
<td>- VL (viral load); CBC (complete blood count); LFTs (liver function tests); Chem (chemistry panel); TSH (thyroid stimulating hormone).</td>
</tr>
</tbody>
</table>

Continued on page 5
HCV... (continued from page 4)

use a nurse or other staff person to regularily check in with patients who are receiving HCV treatment so that side effects can be rapidly addressed.

One suggestion for reducing the cost of managing chronically HCV infected individuals in corrections is to make use of existing "chronic disease" clinic infrastructure and expertise. Because of the high cost of treatment, time spent preparing patients and supporting them while on treatment is likely to be cost effective.

HIV and HCV coinfection

Cellular immune response (T helper cells or CD4 T cells and Cytotoxic T lymphocytes or CD8 T cells) is involved in mounting an immune defense against the virus. Clearly, HCV infected individuals who also have advanced HIV infection may be less able to respond to HCV infection due to their compromised cellular immune response.

Analyses of the effect of HCV and HIV coinfection on progression of either disease are often confounded by concurrent risk factors for progression. However, available data seems to indicate that HIV infection accelerates HCV liver disease. Persons who are co-infected (HIV / HCV) appear to have a 12 to 30 fold higher risk of developing hepatocellular carcinoma than non-carriers. Furthermore, antiretroviral agents can contribute to liver inflammation, and this may be more frequent in those who have underlying chronic hepatitis due to HCV or HBV.

Ritonavir appears to be one of the ART medications that is most commonly associated with liver inflammation in HCV/HIV co-infected patients. The impact of HCV infection on HIV infection is less clear. In some studies, HCV infection does not appear to have an effect on the progression of HIV. Other studies have reported an association between more rapid progression to AIDS or death in HIV-infected patients; particularly among those who were co-infected with HCV genotypes 1a and 1b. However, a report by Sulkowski at CROI contraindicated these findings, suggesting that risk of progression was more linked to lack of access to medical care (for HIV) in his cohort of African American patients who had HIV and HCV coinfection (CROI abstract 34).

Response to HCV therapy in individuals who also have HIV infection appears to be equivalent to that of non-HIV infected individuals. A recent study in the Journal of the American Medical Association by Sulkowski et al. indicates that 88% of co-infected patients tolerate concurrent HCV treatment and HAART. Following successful HCV treatment, co-infected patients are not more likely to relapse after HCV treatment than are patients who do not have concurrent HIV infection.

Currently, when exclusionary criteria are not present (see Table 2), treatment of hepatitis C is recommended for patients when CD4 and viral load values reflect good response to antiretroviral treatment. Although some controversy remains in regard to the definition of a good response to HAART, a stable CD4 T cell count greater than 200 with a stabilized viral load less than 400 is generally accepted.

Conclusion

In summary, the high prevalence of hepatitis infections among incarcerated individuals and the availability of treatments with less than 100% efficacy forces difficult decision making in correctional health facilities. Combination IFN/ribavirin therapy is now the standard of care. National guidelines and standards for selecting patients who are to be treated, while providing access to care for HCV infected individuals regardless of incarceration status, are forthcoming from the CDC. The cost of HCV treatment is expected to be a major barrier to wide implementation of the guidelines in prisons and jails. Correctional physicians eagerly anticipate further guidance from state and federal health officials on supplemental sources of funding for HCV treatment initiatives in correctional settings.

REFERENCES:

1. CDC consultants’ meeting, Recommendations for Prevention and Control of Viral Hepatitis in Correctional Settings. March 5-7th 2001, Crowne Plaza Ravinia Hotel, Atlanta GA
**HEPPigram Part I: Management and Treatment of Chronic HCV**

This information has been adapted and reproduced with permission from CMS, Inc., St. Louis, MO, the developer of the work. It is solely for the educational use of the provider and is not meant to substitute for the individual medical judgment of the provider. Expert consultation is advised.

**STEP 1: Medical Evaluation**

- **Medical Evaluation:**
  - History and Physical
  - Patient education
    - Liver damage prevention
    - Disease transmission
  - Lab testing, liver function (ALT)

- **Is ALT elevated 1.5x upper normal??**
  - **YES**
    - Complete Hepatitis C Medical evaluation utilizing evaluation form (see HEPPigram Part II). Does patient meet additional criteria for treatment?
  - **NO**
    - Stop: Does not meet criteria for HCV Therapy

- **YES**
  - Refer for liver biopsy.

- **NO**
  - Stop: Continue to monitor ††

**NORMAL RESULTS:**
Do not treat but continue to monitor.

**MILD HISTOLOGIC FINDINGS:**
If patient does not wish to be treated, continue to monitor and biopsy periodically (See Table 3, main article).

**ABNORMAL RESULTS:**
Initiate treatment by proceeding to step 2.

**STEP 2: Treatment and Management**

- **Patient meets criteria for therapy (Step 1).**
  - Educate patient about vaccines††, treatment side effects, and obtain consent for treatment.

  - **Initiate therapy under direction of a specialist. Obtain genotype (will determine length of treatment. See HCV 101)**

  - **Evaluate for side effects (see HCV 101)**

  - **YES**
    - Mild side effects: Administer drug in the evening. Reassure patient. Antipyretics prior to q dose.
    - Severe side effects: May require dosage adjustment or discontinuation of therapy.

    - **YES**
      - Consider treatment failure and discontinue therapy.
    - **NO**
    - If genotype 1a or 1b, continue therapy for 6 more months. If non-genotype 1, discontinue.

    - **Examine patient monthly and monitor ALT.**

  - **NO**

    - **YES**
      - Check ALT and HCV RNA at end of therapy. Is ALT normal and HCV RNA negative at 12 months?

      - **YES**
        - Recheck ALT and HCV RNA 6 months after end of therapy to evaluate effectiveness of therapy.
      - **NO**
        - Consider treatment failure and discontinue therapy.

    - **NO**
      - Stop. Continue to monitor ††

****Different institutions may use different criteria for eligibility

†† Hepatitis A and Hepatitis B vaccination are recommended if immunity is not already established.
HEPPigram Part II: One Approach to Hepatitis C Medical Evaluation

This information has been adapted and reproduced with permission from CMS, Inc., St Louis, MO, the developer of the work. It is solely for the educational use of the provider and is not meant to substitute for the individual medical judgment of the provider. Expert consultation is advised.

<table>
<thead>
<tr>
<th>RATIONAL</th>
<th>OBJECTIVE</th>
<th>FINDINGS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screen for HCV Infection if risk factors (blood products before 1990 or IDU in patient with increased ALT), no confirmatory test needed.</td>
<td>Positive HCV-EIA?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Confirm chronic hepatitis elevated ALT (three tests, &gt;1 month apart over previous 12 months, average &gt;1.5 x upper normal).</td>
<td>#1 ALT date #2 ALT date #3 ALT date Average &gt;1.5x upper normal?</td>
<td>Yes No</td>
</tr>
<tr>
<td>No evidence of treatment benefit if under age 18 or over 60 years of age</td>
<td>Age Age &gt;18 and &lt;60?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Treatment for HCV is lengthy with significant side effects.</td>
<td>Has patient received education regarding length of therapy, possible side effects, and expected outcomes and consents to therapy?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Ribavirin causes birth defects.</td>
<td>Willing to use contraception if released during treatment and for 6 mos post treatment? Woman HCG negative?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Heavy ethanol use or injecting drug use will eliminate HCV treatment benefit.</td>
<td>Free of substance abuse misconduct guilty findings for previous 12 months? Consents to random drug testing?</td>
<td>Yes No</td>
</tr>
<tr>
<td>HCV progresses slowly and therapy is problematic; treatment must be completed while incarcerated. If not able to complete treatment courses during incarceration, treatment should be deferred until release.</td>
<td>Maximum release date: Maximum release date in &gt;18 months?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Hepatitis C treatment is arduous, which makes patient adherence and compliance mandatory.</td>
<td>History of non-compliance to medical therapy and/or follow-up?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Interferon worsens hyperthyroidism.</td>
<td>TSH: Results indicate hyperthyroidism?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Interferon worsens autoimmune disease: SLE, rheumatoid arthritis, MCTD, Scleroderma, etc.</td>
<td>Convincing evidence of autoimmune disease?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Interferon causes solid organ transplant rejection.</td>
<td>History of solid organ transplant?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Interferon reduces platelets, especially in the first 4-6 weeks.</td>
<td>Platelet count Platelets &lt;100,000?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Interferon in combination with ribavirin will decrease Hbg 2.5-3.1 in 4-6 weeks.</td>
<td>Hbg: Hbg within normal limits?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Interferon in combination with ribavirin will reduce WBC’s.</td>
<td>WBC: WBC’s within normal limits (&gt;3,000cells/cubic ml)?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Interferon therapy in combination with ribavirin may exacerbate cerebrovascular disease.</td>
<td>Does patient have a history of cerebrovascular disease?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Interferon therapy in combination with ribavirin may exacerbate heart failure.</td>
<td>Does patient have history of coronary artery disease or heart failure?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Interferon therapy in combination with ribavirin can cause renal failure.</td>
<td>Is serum creatinine stable at &lt;2.0?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Interferon may cause or exacerbate major depression.</td>
<td>History of major depression or suicide ideation? History of major psychiatric illness?</td>
<td>Yes No</td>
</tr>
<tr>
<td>Co-infection of HIV and HCV requires that HIV be controlled.</td>
<td>HIV Ab positive? HIV Ab: Date: Viral load:</td>
<td>Yes No</td>
</tr>
<tr>
<td>Co-infection with HBV and HCV may require higher doses of interferon.</td>
<td>HbsAg:</td>
<td>Yes No</td>
</tr>
</tbody>
</table>
## Hepatitis C Treatment

<table>
<thead>
<tr>
<th>TREATMENT (Trade Name)</th>
<th>COST^ (Manufacturer)</th>
<th>DOSE</th>
<th>FREQUENCY</th>
<th>MAJOR SIDE EFFECTS^^</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Combination Therapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ribavirin: oral antiviral agent**+</td>
<td>Ribavirin: $1.25 per 200mg capsule 1000mg: $43.75/week 1200mg: $52.50/week</td>
<td>Ribavirin: 200mg capsules (1000mg/day divided BID or &lt;75kg: 1200mg/day divided BID for &gt;75kg)</td>
<td>2x day</td>
<td>Primary toxicity: hemolytic anemia (reductions of hemoglobin levels occurred within the first 1-2 weeks of therapy).</td>
</tr>
<tr>
<td>Interferon alfa-2a, interferon alfa-2b, consensus interferon</td>
<td>See below for interferons.</td>
<td>Interferons: 3 million units (MU) /injection; consensus interferon 9 mcg/injection.</td>
<td>3x week sub-cutaneous</td>
<td>Rebetron: cardiac and pulmonary events associated with anemia occur in approximately 10% of patients. Psychiatric events in treatment naive: insomnia (39%), depression (34%), irritability (27%).</td>
</tr>
<tr>
<td>Rebetron** 1200 (Schering-Plough):</td>
<td>$391.00 per week</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rebetron** 1000:</td>
<td>$354.00 per week</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rebetron 600:</td>
<td>$290.00 per week</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Monotherapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interferon alfa-2a (Roferon A)</td>
<td>$36.72 per 3MU (Roche)</td>
<td>3 MU/injection</td>
<td>3x weekly sub-cutaneous</td>
<td>Most patients experience flu-like symptoms: headache, dizziness, nausea/vomiting, diarrhea, depression, irritability, insomnia.</td>
</tr>
<tr>
<td>Interferon alfa-2b (Intron A)</td>
<td>$40.00 per 3 MU (Schering-Plough)</td>
<td>3 MU/injection</td>
<td>3x weekly sub-cutaneous</td>
<td></td>
</tr>
<tr>
<td>Peginterferon alfa 2b (PEG-Intron. Pegasys by Roche is expected later this year)</td>
<td>100mcg/ml : $240.00 160mcg/ml : $253.00 240mcg/ml : $265.00 300mcg/ml : $279.00 (Schering-Plough)</td>
<td>Monotherapy: 1mcg/kg per week Combination therapy: 1.5mcg/kg per week</td>
<td>1x weekly</td>
<td>Some patients experience: Neutropenia, Thrombocytopenia, Depression, Anemia</td>
</tr>
<tr>
<td>Interferon alfacon-1 (Infergen)</td>
<td>$38.76 per 9ug(Amgen)</td>
<td>consensus interferon 9 mcg/injection.</td>
<td>3x weekly</td>
<td></td>
</tr>
</tbody>
</table>

---

*Reserve for patients who have contraindications to Ribavirin.

**Currently, Ribavirin is only available from Schering-Plough packaged with Interferon alfa-2b as Rebetrorn or compounded by Fisher's Pharmacy (3904 Perrysville Ave., Pittsburgh, PA 15214; 888-347-3416). Rebetrorn contains Interferon 3 MU plus 1200mg, 1000mg, or 600mg Ribavirin, and is packaged in 2 week supplies.

^ The pricing shown should be considered a maximum price. Substantially discounted pricing may be available based upon the type of pharmacy purchasing medications (ex. institutional, retail, government operated). In addition, quantity or market share rebates from the manufacturer may be available. Prices are subject to change at any time.

^^ Most of the reported adverse reactions are considered mild to moderate and are manageable.

DETAILS ARE IN TEXT

---

CME is Now Available Online at www.hivcorrections.org:
HEPP readers are now able to take HEPP News’ continuing medical education (CME) tests online at http://www.HIVcorrections.org. Any internet browser will enable you to take the HEPP News CME tests every month. Your test results will be registered with the Brown Medical School Office for Continuing Medical Education. When you pass the test, you can either download your CME certificate from the website or request Brown to send the certificate in the mail. Try it out this week!
HEPP News includes new focus on Hepatitis C

Almost one third of our nation’s Hepatitis C cases occur among recently released prison and jail inmates. For this reason, HEPP News has expanded its focus to include topics on Hepatitis C. Our new name is the HIV and Hepatitis Education Prison Project (our acronym will remain the same: HEPP).

We are happy to announce new members of our advisory board, Dr. Dean Rieger, Medical Director of the Indiana Department of Corrections, and Dr. Josiah Rich, Associate Professor of Medicine and Community Health, Brown University School of Medicine, and Attending Physician at The Miriam Hospital.

We would also like to acknowledge our financial supporters for the year 2001, and thank those that funded us last year. Renewing our annual support, HEPP News is grateful for the unrestricted educational grants from Abbott Laboratories, Agouron Pharmaceuticals, Boehringer-Ingelheim/Roxane Laboratories, DuPont Pharmaceuticals, Merck & Co., and Roche Pharmaceuticals. Schering-Plough Corporations has joined our supporters. In addition, OrthoBiotech has contributed baseline support.

HEPATITIS C Rising in Arizona State Prisons

Hepatitis C (HCV) is on the rise in Arizona state prisons. While an estimated 1.4 million HCV-infected prisoners spend time in the nation’s jail system each year, Arizona estimates that approximately 6,000 of its 26,800 inmates are infected with the disease. Prison doctors estimate that between 700 and 1,000 are eligible for treatment; however, who will pay for that treatment is causing controversy. Treating HCV would cost the Arizona Department of Corrections between $8,700 and $16,200 per eligible inmate. (Madrid D. Denver Post. 2/17/01 P. A28. www.denverpost.com)

Hidden Behind Bars: Hepatitis C

Hepatitis C in prisons has picked up attention from the Reuters News Service, a backbone for the general press. An April 5 Reuters report included commentary from HEPP News editor Anne De Groot, Ted Hammett of Abt Associates and HEPP News Advisor, and various national HCV and HIV prison experts. The article calls Hepatitis C “a silent killer” and reported that medical experts say HCV is not only rampant among the almost two million inmates of U.S. prisons and jails, but authorities are not making enough effort to combat it. Reuters interviewed Hammett about a study he conducted for the Texas prison system which concluded it would cost $40 million a year to diagnose and treat prisoners for hepatitis C in that state. The complete story is available at www.reuters.com or by calling the Washington newsroom 202-898-8300.

New Releases: Pegylated Interferon

Schering-Plough has received FDA approval for use of Peginterferon alfalfa-2b (PEG-Intron) in monotherapy, and is expected approval for use with Ribavirin later this year. Peginterferon alfalfa-2b is a longer-acting form of interferon alfalfa-2b (Intron A) that is a once-weekly therapy designed to optimize the balance between antiviral activity and elimination half-life. Roche Laboratories is also expecting approval for their Peginterferon alfalfa-2b, known as Pegasys. Both companies have reimbursement plans for their Hepatitis C medications. For Schering-Plough, call Commitment to Care at 1-800-521-7151 (9:00am-8pm). For Roche’s reimbursement plan, call the Hepline Reimbursement Hotline 800-443-6676, option 3 (8:30am-5:00pm). For more information, call Schering-Plough at (908) 298-4000 or visit http://www.pegintron.com, and call Roche at 800-526-6367 or visit: http://www.rocheusa.com.

The Price of Punishment


Combination Therapy

Projects in Knowledge (slide sets and CME materials supported by an unrestricted grant from Schering Oncology/Biotech) http://www.projectsinknowledge.com/ HepC-DDW/home.htm

Hepatitis C Awareness News is a free educational newsletter. Staff and inmates can subscribe by writing to: Hepatitis C Awareness Project, PO Box 41803, Eugene, OR 97404.

HEPATITIS WEBSITES:
CDC hepatitis home page http://www.cdc.gov/ncidod/diseases/hepatitis/index.htm


American Liver Foundation http://www.liverfoundation.org

Canadian Hepatitis information website http://www.hepnet.com/index.html

HCV Advocate: News and information website on HCV and HIV/HCV coinfection http://www.hcvadvocate.org


Resources
Self-Assessment Test for Continuing Medical Education Credit

Brown Medical School designates this educational activity for 1 hour in category 1 credit for Bloodborne Pathogens Universal Precautions and the AMA Physician’s Recognition Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. A minimum of 70% of the questions must be answered correctly.

This activity is eligible for CME credit through August 31, 2001. The estimated time for completion of this activity is one hour and there is no fee for participation.

1. Which of the following indicate the correct schedule(s) for HBV vaccine?
   a) 0, 6, 12 months  
   b) 0, 1, 4 months  
   c) 0, 2, 6 months  
   d) 0, 3, 6 months  
   e) a and b  
   f) b and c  

2. A patient infected with HCV genotype 2 who is eligible for treatment can expect which duration for treatment?
   a) 16-week (4 month) course of combination therapy  
   b) 24-week (6 month) course of combination therapy  
   c) 48-week (12 month) course of combination therapy  
   d) 6-12 months of therapy; depending on weather LFTs show response to treatment.  

3. At what point should you consider treatment failure and discontinue therapy?
   a) After initiating therapy if patient presents severe side effects.  
   b) At 6 months, if HCV RNA remains positive.  
   c) At 12 months, if HCV RNA remains positive.  
   d) All of the above.  
   e) None of the above; treatment success cannot be measured until after therapy is complete.  

4. Which of the following statements are false?
   a) Persons being treated for HCV should use contraception during treatment and for 6 months post treatment because ribavirin can cause birth defects.  
   b) Interferon in combination with ribavirin can exacerbate cerebrovascular disease and heart failure, and can cause renal failure.  
   c) Treatment for HCV is lengthy with significant side effects, therefore should not be initiated in the correctional setting.  
   d) Monotherapy should only be used for patients who have contraindications for ribavirin.  
   e) a and b.  
   f) b and c.  

5. Indicate which of the following statements are true about HCV and HIV coinfection:
   a) Persons who are co-infected (HIV/HCV) appear to have a 12 to 300 fold higher risk of developing hepatocellular carcinoma than non-carriers.  
   b) HIV infection accelerates HCV liver disease.  
   c) A majority of patients can tolerate concurrent treatment for HCV and HIV.  
   d) a and b.  
   e) All of the above.  
   f) None of the above.  

6. Approximately ___ of US HCV infections occur in people released from prisons or jails:
   a) 2%  
   b) 11%  
   c) 24%  
   d) 30%  
   e) 50%  

HEPP News Evaluation

1. Please evaluate the following sections with respect to:
   educational value  
   clarity  
   Main Article  5  4  3  2  1  5  4  3  2  1  
   HEPPigram  5  4  3  2  1  5  4  3  2  1  
   HCV 101  5  4  3  2  1  5  4  3  2  1  
   Save the Dates  5  4  3  2  1  5  4  3  2  1

2. Do you feel that HEPP News helps you in your work?  
   Why or why not?

3. What future topics should HEPP News address?

4. How can HEPP News be made more useful to you?

5. Do you have specific comments on this issue?

For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.

Name ____________________________________________ Degree ____________________
Address ________________________________________________________________________________________
City ______________________________________ State ________ Zip ______________________
Telephone __________________________________ Fax ______________________________________

BROWN MEDICAL SCHOOL • OFFICE OF CONTINUING MEDICAL EDUCATION • BOX G-A2 • PROVIDENCE, RI 02912

The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

The use of the Brown Medical School name implies review of the educational format and material only. The opinions, recommendations and editorial positions expressed by those whose input is included in this bulletin are their own. They do not represent or speak for the Brown Medical School.

April 2001 • Volume 4, Issue 4 • visit HEPP News online at www.hivcorrections.org